The Chylomicron: Relationship to Atherosclerosis by Tomkin, Gerald H. & Owens, Daphne
Hindawi Publishing Corporation
International Journal of Vascular Medicine
Volume 2012, Article ID 784536, 13 pages
doi:10.1155/2012/784536
Review Article
The Chylomicron:Relationship to Atherosclerosis
GeraldH.Tomkin1,2 andDaphne Owens1,2
1Diabetes Institute of Ireland, Beacon Clinic, Sandyford, Dublin 18, Ireland
2Trinity College Dublin, Dublin 2, Ireland
Correspondence should be addressed to Gerald H. Tomkin, gerald.tomkin@tcd.ie
Received 20 June 2011; Accepted 8 August 2011
Academic Editor: Manuel Castro Cabezas
Copyright © 2012 G. H. Tomkin and D. Owens. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
The B-containing lipoproteins are the transporters of cholesterol, and the evidence suggests that the apo B48-containing
postprandial chylomicron particles and the triglyceride-rich very low density lipoprotein (VLDL) particles play an important
part in the development of the plaque both directly and indirectly by their impact on LDL composition. The ratio of dietary
to synthesised cholesterol is variable but tightly regulated: hence intervention with diet at best reduces serum cholesterol by
<20% andusually <10%. Statins are the mainstay of cholesterol reduction therapy, but they increase cholesterol absorption, an
example of the relationship between synthesis and absorption. Inhibition of cholesterol absorption with Ezetimibe, an inhibitor of
Niemann Pick C1-like 1 (NPC1-L1), the major regulator of cholesterol absorption, increases cholesterol synthesis and hence the
valueofaddinganinhibitorofcholesterolabsorptiontoaninhibitorofcholesterolsynthesis.ApoB48,thestructuralproteinofthe
chylomicron particle, is synthesised in abundance so that the release of these particles is dependent on the amount of cholesterol
and triglyceride available in the intestine. This paper will discuss cholesterol absorption and synthesis, chylomicron formation,
and the eﬀect of postprandial lipoproteins on factors involved in atherosclerosis.
1.Introduction
The formation of the chylomicron is complex. In healthy
humans virtually all fat is absorbed, but cholesterol is
tightly regulated depending on body needs. A very ﬂexible
m e c h a n i s mh a se v o l v e dt ok e e ps e r u mc h o l e s t e r o li na
very narrow range. The chylomicron is responsible for the
transport of medium- and long-chain fatty acids, together
with cholesterol into the lymph. Apo B 48, the solubilising
protein for the chylomicron, is secreted by the entrecote.
Unused protein is degraded, a mechanism that ensures that
there is suﬃcient apo B48 for even the largest fat meal. Fat
feeding increases apo AIV expression, and apo A1V serves as
a surface component for apo B48 particles in the entrecote
[1, 2]. Apo A IV may stimulate net transfer of membrane
triglyceride to luminal particles. It has been suggested that
this occurs due to an increase in microsomal triglyceride
transfer protein (MTP) at the pretranslational level [3]. The
chylomicron particle comes in many sizes; thus the excessive
fat load may be carried by an increase in particle numbers
and/or size. Chylomicron assembly may involve 3 major
processes: assembly of primordial lipoproteins, formation of
lipid droplets, and core expansion [4].
2. The Chylomicron
The chylomicron is assembled mainly in the ER and is
thentransportedtothecis-golgiinprechylomicrontransport
vesicles (PCVs) [5–7]. The secretion of the particles from the
intestine is regulated by MTP. Among the functions of MTP
is the ability to initiate the incorporation of lipids into apo
B preventing apo B degradation. MTP acts as a chaperone to
assist in apo B folding [8] (For excellent review of intestinal
lipid absorption see Iqbal and Hussain [9]). Inhibitors of
MTP in the intestine cause steatorrhoea are associated with
weightlossandareductionincholesterolandtriglyceridesin
human studies [10].
The chylomicron may be thought of as a particle that has
as its main function the transport of fat from the intestinal
lumen to the liver. On the way to uptake by the liver, the
chylomicron divests itself of lipid to the adipocyte for storage
or the muscle and other cells for energy. It also carries2 International Journal of Vascular Medicine
cholesterol which is made available following the controlled
absorption under the regulation of NPC1L1 and ATP bind-
ing cassette proteins (ABC) G5/G8. Chylomicron cholesterol
is also available from the enterohepatic circulation and from
de novo synthesis by the enterocyte. To study the chylomi-
cron particle formation it is interesting to examine the eﬀects
of insulin resistance, a condition associated with an increase
in chylomicrons. The fructose-fed hamster is a model of
diet-induced insulin resistance. Wong et al. [11] examined
the proteomic proﬁles of prechylomicron transport vehicles
(PCVs) isolated from the enteric endoplasmic reticulum in
the small intestine. They found a number of PCV-associated
proteins to be diﬀerentially expressed in these animals
including MTP, apo B48, Sar-1, and vesicle-associated mem-
brane protein 7 (VAMP-7). Glucagon-like peptide-2 (GLP-
2), a gastrointestinally derived intestinotropic hormone
that links nutrient absorption to intestinal structure and
function, was administered to hamsters and was found to
increase secretion of apo B48, triglyceride-rich lipoprotein
(TRL), and cholesterol mass. GLP 2 directly stimulated apo
B48 secretion in jejunal fragments cultured ex vivo [12].
They further suggest that GLP2 represents a nutrient signal
that regulates intestinal absorption of lipid and the assembly
and secretion of chylomicrons from intestinal enterocytes.
CD36 is a member of the class B scavenger receptor family
of cell surface proteins, and the ability of GLP2 to increase
intestinal lipoprotein production was lost in the CD36 −/−
mice suggesting that the mechanism of action of GLP2 is
through CD 36.
Toexaminehowcholesterolmightinﬂuencethechylomi-
cron it is interesting to consider the impact of plant sterols
which lower intestinal absorption of cholesterol. Amiot et
al. [13] have recently shown that plant sterol esters reduced
meal-derived labeled cholesterol in chylomicrons but did
not alter triglyceride hydrolysis or change chylomicron lipids
nor the time course of postprandial chylomicron lipid
increase. Ezetimibe inhibits NPC1L1 by binding to the
protein and preventing conformational changes necessary
for translocation of cholesterol across the membrane [14].
Bozzetto et al. [15] examined the role of Ezetimibe both
fasting and after a standard meal in type 2 diabetic patients.
They found that Ezetimibe added to a statin signiﬁcantly
decreased chylomicron cholesterol and triglyceride concen-
trations and postprandial apo B48. Masuda et al. [16]h a v e
shown that Ezetimibe inhibits postprandial hyperlipidaemia
in patients with Type 2b hyperlipidaemia. CD 36 deﬁcient
mice have enhanced synthesis of chylomicrons in the small
intestine. Sandoval et al. [17] showed that Ezetimibe reduces
postprandial hyperlipidaemia in both wild-type and CD36
KO mice. They showed that triglyceride content and apo
B48 mass were decreased and intestinal mucosal mRNA
expression of fatty acid transfer protein 4 and apo B, along
with fatty acid binding protein 2 (FAB2), diacylglycerol O-
acyltransferase (DGAT)-1 and -2, and stearoyl-CoA desat-
urase (SCD)-1 which is involved in the synthesis and regula-
tion of unsaturated fatty acids, were downregulated. It seems
therefore that Ezetimibe has more actions than just down
regulatingcholesterolabsorption, andthesestudiesmayhelp
inevaluatingtherole ofcholesterolin chylomicronassembly.
It is particularly diﬃcult to understand how triglyceride
absorption is altered since Ezetimibe has not been shown
to cause weight loss or steatorrhoea. Turnover studies might
help to understand the role of NPC1-L1 in fat metabolism. It
is possible that increased chylomicron particle clearance, due
to the smaller load, plays a part in the above results.
3. Niemann PickC1-Like1
The discovery of Niemann Pick C1-like1 (NPC1L1) is an
interesting story. The search for an explanation as to how
cholesterol in the body is so ﬁnely regulated has been
intensive. The ﬁnely tuned regulation of cholesterol was
perhapsbestillustratedbythereportoftheelderlygentleman
w h oa t e2 5e g g sad a yf o rm a n yy e a r sb u th i sc h o l e s t e r o l
remained at just above 6mmol/L [18]. Altman and Davis
in their search for molecules that might inhibit cholesterol
absorption discovered by chance a compound which is now
known as Ezetimibe [19]. They discovered a putative gene,
the Niemann Pick C1-like1 (NPC1-L1). Elegant studies in
mice demonstrated that knocking out this gene reduced
cholesterol absorption by the same amount as happened
when the wild mice were fed with Ezetimibe. They showed
that there was no further reduction in cholesterol absorption
in the knockout mice when fed Ezetimibe. The group
went on to show that lack of NPC1L1 in apoE−/− mice
results in a signiﬁcant reduction in cholesterol absorption
and plasma cholesterol levels and caused a nearly complete
protection from the development of atherosclerosis, under
both cholesterol-fed and non-cholesterol-fed conditions [20,
21]. Weinglass et al. [14] have shown that Ezetimibe binds to
a site distinct to the site where cholesterol binds, preventing
conformational changes in NPC1L1 that is necessary for
translocation of cholesterol across the membrane. Statins,
which inhibit HMGCoA reductase and cholesterol synthesis,
have been shown to increase cholesterol absorption. It
has also been shown that low absorbers of cholesterol
respond better to statins than high absorbers [22]. Ezetimibe
potentiates the eﬀect of statins, increasing their eﬀectiveness
by another 15–20% in relation to cholesterol lowering.
Tremblay et al. [23] reported an increase in NPC1L1 by
19% on atorvastatin thus describing a mechanism whereby
cholesterol absorption is increased in patients on statins. The
mechanism of action of NPC1L1 has recently been further
elucidated. It has been shown that cholesterol promotes the
formation and endocytosis of NPC1L1 which appears to be
an early step in cholesterol uptake. Zhang et al. [24]h a v e
discovered that it is the N-terminal domain of NPC1L1 that
binds cholesterol. It is interesting that this domain does
not bind to plant sterols; thus it now seems that plasma
membrane-bound NPC21L1 binds exogenous cholesterol
and this binding facilitates the formation of NPC1L1-ﬂotiln-
cholestrerol microdomains that are then internalized into
cells through the clathrin AP2 pathway. In animal studies we
have demonstrated an increase in cholesterol absorption in
diabetes [25]; we asked the question as to whether diabetes
might be associated with an increase in cholesterol absorp-
tion through stimulation of NPC1-L1. We demonstrated in
animalmodelsofdiabetesthatNPC1L1wasupregulated[26]International Journal of Vascular Medicine 3
and in diabetic patients, and we demonstrated an increase in
NPC1L1mRNA[27]suggestingamechanismforanincrease
in cholesterol absorption. In the Psammomys Obesus, a
model of type 2 diabetes, the animals exhibiting weight gain,
hyperinsulinaemia, and hypercholesterolaemia, NPC1-L1
protein and gene expression were both signiﬁcantly reduced
in the intestine, and the authors found a lower capacity to
absorb cholesterol compared to controls [28]. This may sug-
gest interspecies variation but it is a surprising ﬁnding con-
sidering that this animal model of diabetes has been shown
to have increased production of intestinal lipoprotein-
containing apo B48 [29]. Ezetimibe has been shown to bind
to the brush border and to NPCILI-expressing cells, [30].
There is a sterol regulatory element in the promoter and a
sterol-sensing domain of NPCILI which appears to regulate
cholesterol absorption in response to cholesterol intake. Huﬀ
et al. [31] have shown that NPC1L1 is suppressed in mice
given a cholesterol-rich diet and increased in the cholesterol-
depleted porcine intestine. The nuclear receptor, peroxisome
proliferator-activated receptor (PPAR) delta/beta, appears
to control the expression of NPC1L1. Activation by a
synthetic agonist of PPAR delta has been shown to reduce
cholesterol absorption and reduce expression of NPC1L1
without altering ABC G5/8 [32]. Tremblay et al. [23]h a v e
shown that Atorvastatin increases Niemann Pick C1L1 in the
intestineanddecreasedABCG5/8whichleadstoanincrease
in cholesterol absorption. These ﬁndings were accompanied
by an increase in the transcription factors, sterol regulatory
binding protein (SREBP) 2 and hepatic nuclear factor
(HNF)-4. There may be other transporters of cholesterol,
for example, scavenger receptor class B type 1 (SR-B1) [33]
which is located both in the apical and basolateral mem-
branes of the enterocyte. They may also play a role in choles-
terol absorption. (For review see Iqbal and Hussein [9]).
4.ATP BindingCassetteProteinsG5andG8
The mechanism whereby the body is almost completely
unable to absorb plant sterols was a mystery until recently.
Study of the familial condition, sitosterolaemia, unlocked
the mystery [34]. Sitosterolaemia is a rare condition asso-
ciated with early and severe atherosclerosis. The condition
is associated with normal or slightly elevated cholesterol
whereas total sterols are markedly increased. Search for
polymorphisms in putative genes, controlling plant sterol
absorption or perhaps one should say blocking plant sterol
absorption, identiﬁed ATP binding cassette proteins (ABC)
G5 and G8 in the intestine [35]. Further work demonstrated
that these two gene products work in tandem to reexcrete
both plant sterols virtually completely and cholesterol to
a lesser extent in a regulated way [36]. The genes were
also found to be expressed in the liver where they are
responsible for controlling cholesterol reexcretion into the
bile [37]. It appears that these two genes are very important
regulators of cholesterol and together with NPC1-L1 protein
are responsible for cholesterol homeostasis in the body.
Polymorphisms of the ABCG5/G8 have not only been
associated with increased sitosterol but also with increase in
cholesterol. It has also been shown that polymorphisms in
the ABCG5/G8 may inﬂuence cholesterol in weight reduc-
tion programs (the Q604E SNP in ABCG5 and the C54Y
in ABC8) [38]. Gylling et al. [39] examined polymorphisms
in the ABCG5 and G8 genes and found that low serum
cholesterol and cholesterol absorption were linked to a poly-
morphism (D19H) of the ABCG8 gene and characteristics of
theinsulinresistancesyndromeinmenwerelinkedtoQ604E
polymorphism in the ABCG5 gene. The authors studied 263
mildly hypercholesterolaemic noncoronary subjects using
cholestanol to cholesterol ratio as a surrogate marker of
cholesterol absorption eﬃciency.
Since diabetes is so frequently associated with dyslipida-
emia and atherosclerosis, the ABCs became a target for
research. Bloks et al. [40] examined mRNA and protein
expression of ABCG5 and G8 in the intestine of strep-
tozotosin diabetic rats and found signiﬁcant reduction
in expression of both ABCG5 and G8. They found that
levels were partially normalised on insulin supplementation.
We have shown that ABCG5 and G8 were reduced by
more than 50% in the intestine of zucker diabetic fa/fa
rats compared with lean rats although this did not reach
statistical signiﬁcance [41]. Insulin treatment caused a non-
signiﬁcant increase in ABCG5 and G8 mRNA. In another
study of streptozotosin diabetic rats ABCG5 and G8 were
both very signiﬁcantly reduced in the intestine [26]. There
was a negative correlation between ABCG5 and G8 and
chylomicron cholesterol [26]. In the Psammomys Obesus,
another model of diabetes, Levy et al. [28, 29] showed a
reduction in ABC G5/G8 in the intestine. In the intestine
of human subjects with type 2 diabetes, ABCG5 and G8
mRNA were both signiﬁcantly lower compared to controls
[27]. There was a negative correlation between ABCG5 and
G8 and NCP1-L1 in the combined diabetic and control
subjects [27]. There was a signiﬁcant negative correlation
between chylomicron cholesterol and both ABCG5 and G8
[27]. These two genes appear to play an important role in the
dysregulation of cholesterol metabolism in diabetes.
As stated above inhibition of HMG CoA reductase with
a statin has been shown to decrease ABC G5/8 as well as
increasing NCP1L1 to increase cholesterol absorption [23].
In the Psammomys obesus animal model of type 2 diabetes
the ABC G5 /8 reduction was associated with a reduction
rather than increase in cholesterol absorption perhaps due to
a reduction in NPC1L1 which the authors found, suggesting
ad i ﬀerence between diﬀerent animal models of diabetes
[28].
Calcium appears to regulate lipids, at least in post
menopausal women where supplementation has been shown
to favorably alter lipids. Ma et al. [42] have shown in ham-
sters that improvement was associated with downregulation
of NPC1L1 and MTP mRNA and upregulation of intestinal
ABCG5/8.
5. IntestinalMicrosomal Triglyceride
Transfer Protein
Intestinal microsomal triglyceride transfer protein (MTP)
plays a major role in the ”assembly of the chylomicron parti-
cle and therefore of cholesterol and triglyceride metabolism.4 International Journal of Vascular Medicine
MTP has become a hot topic since inhibitors of intestinal
MTP have been shown to lower triglyceride without causing
hepatic steatosis at least in animal studies [43–45]. Although
many polymorphisms of MTP have been described, some of
which have considerable impact on LDL cholesterol in both
nondiabetic and diabetic subjects [46, 47], it is diﬃcult to
know whether the results mainly stemmed from the eﬀect in
the liver rather than the intestine. The intestinal inhibitors
of MTP which have no eﬀect on the liver should answer this
question in the future. In animal studies, diabetes is associ-
ated with an increase in MTP mRNA with close correlation
between MTP mRNA and chylomicron cholesterol [40, 41,
48, 49]. In the rabbit increased intestinal MTP mRNA is
associated with increase in chylomicron particle numbers
[48], but in the rat it is associated with larger particles
[49]. The fructose-fed insulin-resistant hamster model had
an increase in MTP protein mass, and this was associated
with an increase in the triglyceride-rich intestinally derived
lipoproteins [50]. Zoltowska et al. in 2003 [51] examined the
B48-containing lipoprotein assembly in the small intestine
of Psammomys obesus, a model of nutritionally induced
diabetes and insulin resistance. De novo triglyceride syn-
thesis, apo B48 biogenesis, and triglyceride-rich lipoprotein
assembly were all increased. MTP activity and protein
expression, however, were not altered. In the enterocyte of
fructose-fed golden hamster MTP mRNA and protein mass
were increased by TNFα, but apo B levels in the enterocyte
were not aﬀected suggesting that there is considerable inter
species variation [50]. In human studies in type 2 diabetes
we demonstrated an increase in MTP mRNA in intestinal
biopsies [27, 46]. Diabetic patients who were on statin ther-
apy had lower MTP mRNA compared to those not on statins
[46]. We found positive correlations between MTP mRNA
and chylomicron fraction cholesterol and apo B48 [46].
6. MTP Polymorphism
Intype2diabetesthecommonMTP492G/Tpolymorphism
has been associated with surrogate markers of nonalcoholic
hepatic steatosis [52] .T h eh o m o z y g o u sf o r mo ft h ep o l y -
morphism has been shown to be associated with a higher
concentration of LDL 3 in diabetic patients of Chinese
origin, but there was no eﬀect in the heterozygous subjects
[53]. In nondiabetic subjects heterozygous for the T allele
no changes in LDL triglyceride or cholesterol have been
found whereas the few subjects homozygous for the T
allele had decreased numbers of triglyceride-rich VLDL
particles and signiﬁcantly lower VLDL and LDL cholesterol
[54]. It has been suggested that the T allele might interact
with visceral obesity and hyperinsulinaemia in nondiabetic
subjects [55]. Examination of fasting lipids in a healthy black
male population demonstrated that the rare T/T genotype
was associated with a higher mean level of apo B suggesting
ar a c i a ld i ﬀerence [56]. The eﬀect of the inﬂuence of the G/T
polymorphism on postprandial lipoproteins demonstrated
that the TT polymorphism was associated with an increase
in apo B48 in the smallest triglyceride-rich lipoprotein
fraction postprandially without a diﬀerence in postprandial
triglycerides or in fasting plasma or TRL cholesterol [54].
We have found in diabetic patients that the heterozygous
−493G/T polymorphism was associated with signiﬁcantly
lower LDL cholesterol and in the postprandial period higher
apo B48 in the small chylomicrons [46]. It was a surprise
to us that the −493G/T homozygous subjects who had
lower LDL cholesterol were reported to have an increase
in CHD [57]. Homozygosity of the minor −493 T allele
has been associated with an increased risk of IHD in 2
further studies [58, 59]. These intriguing ﬁndings have been
further investigated by Aminoﬀ et al. [60]. Aminoﬀ et al.
[60] showed that both the MTP polymorphisms −493 G >
T and the 164 T > Cr e s u l ti nl o w e rt r a n s c r i p t i o no fM T P
in vivo in the heart, liver, and macrophage. They showed
in a case-controlled study that the subjects homozygous for
−164 C allele had an increased risk of IHD. These studies,
together with the knowledge that the heart secretes Apo
B-containing lipoproteins, suggest that reduction in MTP
in the heart results in lipid accumulation in the heart and
is followed by IHD or the susceptibility to IHD perhaps
through reduction in availability of free fatty acids for energy
at times of acute stress. Of course another theory is that
just like the liver the decrease in secretion of VLDL through
reduction in MTP function that leads to hepatic steatosis in
theheartleadstoaccumulationoffatthatmaybetoxictothe
myocardium. Last year Bharadwaj et al. [61] demonstrated
that in an animal model VLDL and chylomicron lipids
enter the heart through diﬀerent pathways. A CD36 process
appears to be important for VLDL lipoproteins and a
non-CD36 for chylomicron-derived fatty acid uptake. They
showed that lypolysis is involved in the uptake of core lipids
from triglyceride-rich lipoproteins. AMPK plays a central
role in energy homeostasis. In the heart it increases during
ischaemia and is thought to be implicated in the pathophys-
iology of cardiovascular and metabolic disease. AMPK has
been targeted as being of value in the production of new
therapies for cardiac and metabolic disease. AMPK is insulin
sensitive, and in diabetes a reduction in AMPK activity leads
toadecreaseinmuscleglucoseuptakethusshiftingfuelfrom
glucose to fat for cardiac myocyte function. It is therefore
interesting to speculate that the −493 polymorphism might
be particularly a disadvantage to patients with diabetes.
A further recent link to the possible importance of MTP
activity in the cardiac muscle in diabetes is the ﬁnding
that the redox-sensitive transcription factor NF-E2-related
factor 2 (NrF2) is suppressed by extracellular signaling-
related kinase (ERK) leading to an increase in stress-induced
insulin resistance in cardiac myocytes [62]. The authors
also showed in the hearts of streptozotosin-induced diabetic
mice downregulation of glucose utilization. These studies
demonstrate the importance of the chylomicron and MTP
in cardiac function/dysfunction and may account at least to
someextentfortheworseprognosisinthosediabeticpatients
who have a MI.
7. Regulation of Chylomicron Synthesis
The synthesis of triglyceride in the liver depends on acyl-
coenzyme-A-diacylglycerol acyltransferase (DGAT). This
en-zyme is also found in many other tissues includingInternational Journal of Vascular Medicine 5
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Figure 1: chylomicron synthesis. Dietary triglyceride, phospholipid, and cholesterol, together with intestinally synthesized cholesterol
(for which 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase is the rate-limiting enzyme) and recycled biliary cholesterol
together with intestinally derived ApoB48 are assembled under the inﬂuence of microsomal triglyceride transfer protein (MTP) to form the
chylomicron.Priortoincorporationintothechylomicron,cholesterolisesteriﬁedbyacylcoenzymeA:cholesterolacyltransferase(ACAT)and
the triglycerides are reassembled from fatty acids with acylcoenzyme-A-diacylglycerol acyltransferase (DGAT) catalysing the rate-limiting
step. The cholesterol is transferred across the membrane by Niemann Pick C1 like-1 and some is reexcreted back into the intestinal lumen
by the action of ATP-binding cassette proteins (ABC)G5 and -G8. The particle is assembled under the regulation of microsomal triglyceride
transfer protein and delivered to the lymphatics.
the intestine and white adipose tissue, tissues that are
active in triglyceride syntheis. Two DGAT enzymes have
been discovered, DGAT1 and DGAT 2. These enzymes
catalyse the ﬁnal step of the triglyceride pathway [63], their
substrates being diacyl glycerol and fatty acyl CoA. DGAT-1
deﬁcient mice are resistant to diet-induced obesity and have
increased sensitivity to insulin and leptin [64, 65], hence the
excitment in discovering DGAT inhibitors [66, 67]. DGAT
stimulates PPARs, and PPARa regulates lipid metabolism
through its aﬀect on adipocyte formation. Activation of
PPARawith Fibrates lowers triglyceride through a number of
mechanisms including increasing free fatty acid β-oxidation,
hepatic lipoprotein lipase expression, a reduction in apo
C111, and a reduction in apo B [68]. The mechanism by
which PPARα activation represses apoCIII transcription has
yet to be elucidated. In vitro studies imply repression of
apoCIII expression via interaction with a PPRE in the Rev-
erb-α promoter, since it has been shown that mice deﬁcient
inthisproteinexhibitincreasedplasmaconcentrationsofTG
and apoCIII [69]. Whether apoCIII aﬀects TG metabolism
in vivo is contentious. Some studies showed an eﬀect in
normolipidemic subjects [70, 71]. Increases in the number
and apo CIII content of VLDL particles also have adverse
consequences for other lipoprotein subspecies, contributing
to an increase in small, dense LDL particles [72]. The role
of fenoﬁbrate in the prevention of atherosclerosis is still
disputed with large trials such as the ﬁeld study[73] failing
to demonstrate beneﬁt for primary endpoints although
secondary endpoints suggested that beneﬁt and the DAIS
study [74], an angiographic study in diabetes, certainly
demonstrated signiﬁcant reduction in the progression of
atherosclerotic lesions (Figure 1).
The role of Apo A-IV is of interest as it increases MTP
activity and leads to increased lipidation of the chylomicron
particle (For review see Black [75]). In newborn swine,
intestinal epithelial cells that had overexpressed apo A-
IV increased the lipid content of the chylomicron particle
[76, 77]. Further studies showed that the mechanism was
through upregulation of MTP at the pretranslational level
[78]. A meal rich in fat increases Apo A IV synthesis. During
lipolysis of the chylomicron particle apo A IV binds to
HDL although some circulates free. The function of apo
AIV on HDL is not clear, but reduced levels are associated
with cardiovascular disease, and transgenic overexpression
protects mice fed a high-fat diet from atherosclerosis [79]
suggesting that Apo A IV plays an important regulatory6 International Journal of Vascular Medicine
role in fat absorption and storage. Fasting jejunal lipid
content was examined in morbidly obese persons some of
whom had diabetes [80]. The diabetic subjects had lower
triglyceride levels but Apo A IV mRNA was signiﬁcantly
higher with a signiﬁcant negative correlation between apo
IV mRNA expression and jejunal triglyceride. The diabetic
patients had higher chylomicron triglycerides and apo B48.
In the fructose-fed hamster, a model of insulin resistance, it
has been demonstrated that the intestine is not responsive
to the insulin-induced downregulation of the apo B48
lipoprotein production found in the chowfed animals [81].
The mechanism appears to be through disturbance in the
ERK pathway which involves both insulin signaling and
lipoprotein overproduction. These results are in keeping
with the studies which have shown that insulin resistance
and diabetes are associated with an increase in MTP in
the liver and that MTP is negatively regulated by insulin
[82–84]. In further studies reported by the Toronto group
in 2010 [85] the prechylomicron transport vesicles (PCVs)
were characterized, and proteomic proﬁles were developed.
They have reported that MTP, Apo B48, SAR-1, and VAMP-
7w e r ed i ﬀerentially expressed when compared to the chow
fed animals. The results the authors suggest have increased
our understanding of the assembly and transport of nascent
chylomicrons in insulin-resistant states.
The intestinal enterocyte has a short half-life but yet
manages to ﬁnely control fat absorption so that even the
largest fat meal does not pass through unabsorbed. The
mechanism involves increase in chylomicron number as
shown by increased apo B and increased size as shown
by the fat content of the chylomicron. Dai et al. [86]
examined the mechanism whereby CaCo 2 cells diﬀerentiate
into enterocyte cells and secrete chylomicron-like apo B48
particles when incubated with oleic acid, whereas cells that
go on to become crypt cells do not have this ability. They
foundthatMTPexpressionseemedtobealimitingfactorfor
apoBlipoproteinsecretion.TheyfoundevidencethatHNF1,
HNF4, and DR1 were critical for diﬀerentiation-dependent
MTP induction and that repression was induced by NR2F1
andIRE1B.NR2F1andIRE1Bwerefoundmoreinthecrypts
than in the villi suggesting the mechanism whereby only the
enterocyte has the facility to absorb fat and that MTP is the
limiting factor. These experiments add to the excitement of
intestinal MTP as a target for treatment of dyslipidaemia
in diabetes and other conditions where there is excess of
postprandial chylomicrons.
8. Gene Regulation of Chylomicron Metabolism
A high-fat diet is associated with an increase in triglyceride-
rich lipoproteins. Hern´ andez-Vallejo et al. [87]i n v e s t i g a t e d
the impact of a short-term high-fat diet in mice and showed
that apo B, MTP, and Apo A IV were upregulated to handle
the increased lipid load. They also showed that there was a
suppressionofgenesassociatedwithfattyacidsynthesis,FAS,
ACC,SREBP-1c,andakeyregulatoroflipidbiosynthesiswas
increased and translocated to the nucleus. LXR is considered
to be a central player in energy homeostasis as indicated by
its putative role in lipogenesis, gluconeogenesis, lipoprotein
metabolism, and glucose uptake [88]. SREBP was only
partly dependent on LXR. Apo A5 plays a major role in
the metabolism of triglyceride-rich lipoproteins in the liver
[89]. It is less certain whether apo A-5 plays a part in the
chylomicron metabolis. Recently Guardiola et al. [90]h a v e
demonstrated gene expression mostly in the duodenum and
colon. In vitro studies suggested that the protein may be
functional, but this needs further investigation.
Obesity is associated with an increase in inﬂammatory
cytokinessuchasTNF-a[91].TNFainfusionhasbeenshown
to stimulate the overproduction of intestinal apo B48 as well
as hepatically derived apo B 100 particles [92, 93]. TNF a
increases MTP, and we found MTP to be increased in animal
and human diabetes [26, 27, 48, 49], a condition that is
associated with increased TNFa [94]. Recently Qin et al. [94]
have shown that TNFa increased CD 36 which is, among
other functions, an important fatty acid transporter. Thus
a vicious cycle is put in place whereby excessive feeding
increases chylomicron production which leads to insulin
resistance through deposition of fat which in turn stimulates
TNFa and other cytokines which increase insulin resistance
which increases chylomicron production.
The delipidated chylomicron particle is cleared by the
liver through the LDL receptor-related protein 1, (LDLR-
related protein 1) receptor, and LDL B/E receptor. The LDLR
is insulin sensitive, and the receptor is downregulated in
insulinresistance[95].Throughaseriesofstepsthelipidand
cholesterol are repackaged and excreted by the liver as VLDL
with apoB100 as the solubilising protein. The pathways in
the liver are not dissimilar to those in the intestine, and
like chylomicrons in the intestine, the VLDL particle will
contain some de novo synthesised cholesterol. The liver
like the intestine can regulate, at least to some extent, the
amount of cholesterol in the VLDL particle by regulation
of excretion of cholesterol through the bile. NPC1L1 plays
a part in the liver in the regulation of cholesterol transport.
Hepaticnuclearfactor-1(HNF-1)alphaandsterolregulatory
element binding protein (SREBP)-2 appear to be important
regulators of NPC1L1 in the liver [96]. It has also been
shown that they have important binding sites within the
human NPC1L1 promoter. The role of NPC1L1 in the liver
is probably to divert cholesterol away from excretion in the
bile [97]. A recent study in female Chinese women with
gall stones has shown reduced NPC1l1 mRNA and protein
in the liver and supersaturation of cholesterol in the bile
[98]. Ezetimibe has not been shown to increase the risk of
gall stones perhaps because the drug has its primary eﬀect
in reducing cholesterol absorption. Indeed in the golden
Syrian hamster Ezetimibe reduced diet-induced increase in
biliarycholesterol[99],and,ingallstone-susceptiblemicefed
lithogenic diets, Ezetimibe prevented gall stone formation
[100]. Inhibition of NPC1L1 by Ezetimibe is associated with
an improvement in hepatic steatosis. Jia et al. [101]h a v e
recently investigated the mechanism by deleting NPC1L1 in
mice and inducing hepatic steatosis with a high fat diet.
The knockout mice did not develop steatosis. Hepatic fatty
acid synthesis and mRNA for genes regulating lipogenesis
were reduced, and the knockout animals did not develop
hyperinsulinaemia. Nomura et al. [102] demonstrated inInternational Journal of Vascular Medicine 7
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Figure 2:Chylomicronclearance.ThechylomicronacquiresapoEandapoC111inthecirculation,andmostofthetriglycerideishydrolised
by lipoprotein lipase (LPL) prior to it being cleared by the low density lipoprotein (LDL) B/E receptor or the LDL receptor-related protein
(LRP) receptor in the liver. GPIHB also plays a smaller part in uptake of chylomicron remnants by the liver capillaries.
Zucker rats that Ezetimibe improved hepatic insulin sig-
naling as well as hepatic steatosis in both the liver and in
cultured steatotic hepatocytes. The drug recovered insulin-
induced Akt activation and reduced gluconeogenic genes.
The relevance of this study to humans is not clear as patients
with diabetes whoare treatedwith Ezetimibe do not improve
blood sugar control Kishimoto et al. [103].
9. ChylomicronClearance
Delayed clearance of the chylomicron particle is another
cause of hypertriglyceridaemia. The increased residence time
of the particle potentially increases its atherogenicity and
may be an important factor in the development of small
dense LDL since large triglyceride-rich particles correlate
well with small dense LDL. The delay in clearance of the
chylomicron inevitably leads to a delay in clearance of
VLDL since the apo BE receptor preferentially takes up the
chylomicron particle. The triglyceride-rich lipoproteins may
also be cleared in the liver by heparin sulfate proteoglycans
HSPGs [104–106]. Among the HSPGs are the transmem-
brane syndecans, which have been shown to mediate the
internalisation of model lipoproteins. Syndecan 1 can medi-
ate binding and uptake of chylomicron remnants by HepG2
liver cells [107]. Stanford et al. [108] have shown this in
in vivo genetic studies, using knockdown mice. Williams
[104] showed that glycosylphosphatidyl inositol anchored
high-density lipoprotein binding protein 1 (GPIHBP1) plays
a critical role in the lypolytic processing of chylomicrons.
GIHBP1 is located on the luminal face of the capillary
endothelium and has been shown to bind both LpL and
chylomicrons [109] suggesting that it serves as a platform
for lipolysis drawing the chylomicron and LpL into close
proximity. The role in atherosclerosis of this protein has still
to be explored; however, a missense mutation of GIHBP1
in a young boy with severe chylomicronaemia has been
described, and one presumes that other polymorphisms
with less severe chylomicronaemia will help to unravel the
role in atherosclerosis of this protein. Another cause for
hypertriglyceridaemia is a mutation in HSPGs. Lipoprotein
lipase (LpL) is stored in the subendothelial compartment
awaiting transport. GPIHBp facilitates the transport of
LpL from the subendothelium to the luminal side of the
vasculature [110]. Bishop et al. [111]h a v ed e m o n s t r a t e da
deletionoftheHPSG,Collagen18,whichresultedinreduced
vascular LpL mass and activity in mice and caused mild
hypertriglyceridaemia. Patients with collagen 18 deﬁciency
have Knoblauch syndrome, a rare disorder characterised
primarilybyoculardefects.Thesepatientshavehypertriglyc-
eridaemia (Figure 2)[ 111].
10. Chylomicron and Atherosclerosis
Whereas cholesterol is tightly regulated with carefully
evolved mechanisms to ensure that dietary cholesterol
deﬁciency does not impede the body’s need for cholesterol,
the triglyceride metabolism is exquisitely regulated so that
almost no dietary fat is lost, energy being conserved for later
famine. The atherosclerotic plaque is mostly made up of
cholesterol, fatty acids, and ﬁbrous tissue. The recognition8 International Journal of Vascular Medicine
that, in conditions of severe hypercholesterolaemia such
as familial hypercholesterolaemia and familial combined
hyperlipidaemia, life expectancy was severely reduced due
to atherosclerosis focused attention on cholesterol as being
a major player in the atherosclerotic process. Population
studies have conﬁrmed the association. LDL cholesterol is
the major cholesterol-containing particle. If cholesterol is
measured per particle the LDL particle contains 100-fold
more as compared to the chylomicron and the statins, which
inhibit cholesterol synthesis and have been demonstrated to
lower mostly LDL cholesterol and to reduce atherosclerosis.
This has tended to focus attention even more strongly on
the LDL particle as being the major player in atherosclerosis
to the determent of the chylomicron. The chylomicron
cholesterol content may be low, but the half-life is in minutes
(rather than around 4 days for the LDL particle), hence the
cholesterol carrying power of these particles is enormous
and similar to LDL. More than 10 years ago Karpe et al.
[112] demonstrated a relationship between apo B48 and
carotid atherosclerosis both in normotriglyceridaemic and
hypertriglyceridaemic subjects An argument that the chy-
lomicron particle could not be considered as an atherogenic
particle because of its size and therefore its inability to enter
the subendothelial space is no longer valid since apo B48
has been found in atherosclerotic plaques in both animal
and human studies [113, 114]. Proctor and Mamo [113]
have demonstrated apo B48 in rabbit atherosclerotic plaque.
The authors in elegant studies have also demonstrated that
perfusing both chylomicron remnants and LDL in the rabbit
aorta resulted in an preferential uptake of apo B48 in the
subendothelial space suggesting that the chylomicron does
indeed play a predominant role in the delivery of not
only cholesterol but also of fatty acids to the plaque. Pal
et al. in 2003 examined carotid endarterectomy patients
and found apo B48 in the plaque [114]. These ﬁndings
have been conﬁrmed in humans by other workers [115].
The mechanism whereby the macrophage takes up the
chylomicron particle has been extensively investigated. The
chylomicron remnant competes for uptake of native LDL
through the LDL receptor [116] but an apo B48-speciﬁc
receptor has also been described [117, 118]. Elsegood et al.
[119, 120] have described a 43Kda macrophage chylomicron
remnant binding protein as a candidate for sterol loading
of macrophages resulting in the unabated uptake of chy-
lomicron remnants by macrophages. It has been suggested
that the chylomicron particle contains too little cholesterol
to make it an important transporter of cholesterol to the
atherosclerotic plaque but it must be remembered that the
chylomicron particle number is massive in the postprandial
phase compared to LDL and has a half-life in minutes rather
than in days thus transporting over time, in relative terms,
a similar amount of cholesterol compared to LDL. There
have been as yet no clinical studies that have investigated the
relationship between apo B48 and cardiovascular events, but
it has been suggested that there is enough evidence to mount
such trials [121]. Patients with type 1 diabetes as in type 2
diabetes are at increased risk of atherosclerosis. Mangat et al.
[122]demonstratedincreasedapoB48bothfastingandpost-
prandial in type 1 diabetic patients compared to controls.
Lipoprotein lipase
Chylomicron
Atherosclerosis
Smooth muscle cells
GPIHBP1
HSPG
Endothelium
Figure 3: The chylomicron and atherosclerosis. The atherosclerotic
plaque is composed of a lipid-rich core containing cholesterol and
necrotic tissue and is covered by a ﬁbrous smooth muscle cell
cap. Low density lipoprotein (LDL) is the major contributor to
plaque cholesterol, but chylomicron remnants are also taken up
into the subendothelial space, and because of the rapid turnover
of chylomicrons the amount of cholesterol they can deliver to the
plaque is not reﬂected in serum chylomicron cholesterol. Chy-
lomicrons are delipidated by lipoprotein lipase on the artery wall.
They are attached to the endothelium by high-density lipoprotein-
binding protein 1 (GPIHBP1) and heparin sulphate proteoglycans
(HPSG) which facilitate their uptake into the subendothelial space.
Chylomicron remnants become trapped in the artery wall and
disintegrate to contribute cholesterol to the lipid-rich core.
They also showed that the arterial retention of remnants
ex vivo was increased 7-fold in type 1 diabetes relative to
controls. The authors also showed that the remnants bound
with signiﬁcant aﬃnity to human biglycan in vitro with a
further 2-3-fold increase in binding activity with glycated
glycan. The authors suggest that their ﬁndings support
the hypothesis that impaired remnant metabolism may
contribute to accelerated progression of atherosclerosis. We
and others have shown increased Apo B48 in type 2 diabetes
as compared to controls [123–126]. This abnormality was
improved with better control of diabetes [123]. Taskinens
group [126] has demonstrated an increase in apo B48 in
diabetic patients with CVD as compared to diabetic patients
without atherosclerosis. Finally it should be remembered
that an increase in chylomicron cholesterol leads to and
correlates with both VLDL cholesterol and LDL cholesterol,
and large triglyceride-rich lipoproteins are associated with
the atherogenic smalldense LDL and low HDL. Both of these
ﬁndings demonstrate the importance of the chylomicron in
generating an atherogenic lipoprotein proﬁle (Figure 3).
In conclusion there is clear evidence that chylomicron
metabolism is abnormal in diabetes, a condition which is
associated with a heavy burden of atherosclerosis. There
is good evidence to implicate the chylomicron directly in
the atherosclerotic pathological process, and there is good
evidence that abnormal chylomicron metabolism is associ-
ated with an atherogenic LDL proﬁle. Measures to decrease
chylomicron formation should decrease atherosclerotic bur-
den, and the results of an intestinal MTP inhibitor are
therefore awaited with great interest. Increasing chylomicron
turnover may not prove useful since accelerated metabolism
of the particle may just lead to increased deposition in theInternational Journal of Vascular Medicine 9
plaque and increased VLDL and an increase in small dense
LDL. In both diabetic and nondiabetic subjects it seems
wise to restrict chylomicron formation through strict diet
and in diabetes; meticulous control of blood sugar will
also improve chylomicronaemia. It is time to focus our
attention on the chylomicron as an important player in the
atherosclerotic process. The experimental animal studies and
small human studies make it apparent that the time is right
for large prospective clinical trials to evaluate the dangers
of postprandial chylomicronaemia. With the advent of the
speciﬁc intestinal inhibitors of MTP, it is likely that these
studies will soon be undertaken.
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